Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Vital Therapies crashes after liver therapy fails trial

Vital Therapies Inc lost three-quarters of its market value after the company said its liver therapy failed to meet its main goal in a late-stage study, raising doubts about the future of the treatment. The company said it would stop two ongoing studies of the cell-based therapy, which is aimed at treating alcohol-induced liver diseases […]

Read More »

Samsung Makes First Foray Into U.S. Stock Market

SEOUL—Samsung will make its first entry into U.S. stock markets with an anticipated $1 billion listing of its biotechnology affiliate, according to people familiar with the matter, marking a major step in the South Korean conglomerate’s foray into a new industry outside its better-known electronics business. The listing of Samsung Bioepis Co. on the Nasdaq […]

Read More »

Applied Genetic Surges on $1 Billion+ Eye Deal With Biogen

Gainesville, Fla.-based Applied Genetic Technologies Corporation (AGTC) announced yesterday that its collaboration with Biogen, Inc. has now closed. Originally announced on July 2, 2015, the deal has met all the conditions under the Hart-Scott-Rodino Antritrust Improvements Act of 1976 and is good to go.   The deal, announced in July, was a collaboration and licensing […]

Read More »

U.S. FDA approves ‘female Viagra’ with strong warning

The first drug to treat low sexual desire in women won approval from U.S. health regulators on Tuesday, but with a warning about potentially dangerous low blood pressure and fainting side effects, especially when taken with alcohol.   The U.S. Food and Drug Administration said the pink pill, to be sold under the brand name […]

Read More »

Esperion Rockets as Lead Drug ETC-1002 Will Not Require Heart Trial for FDA Approval

Ann Arbor, Mich.-based Esperion Therapeutics, Inc. (ESPR), announced yesterday that the U.S. Food and Drug Administration (FDA) confirmed LDL-C as an acceptable clinical surrogate endpoint for its trial therapeutic, ETC-1002.   ETC-1002 is designed to lower cholesterol for patients who have not had success using statins, such as Pfizer Inc. (PFE)’s Lipitor. The compound is […]

Read More »

Kite Pharma CEO Refutes Rumors of Death Associated with Experimental Cancer Drug

The death of a patient participating in a Kite Pharma, Inc. (KITE) clinical trial was determined to not be related to the experimental treatment for low-prognosis patients with non-Hodgkin’s lymphoma, Arie Belldegrun, Kite’s chief executive officer said in a conference call this morning.   During the conference call, Belldegrun refuted what he called a “high […]

Read More »

Gilead Rumored to be Eying Achillion…Again

August 17, 2015By Mark Terry, BioSpace.com Breaking News Staff At least one analyst is again speculating that Foster City, Calif.-based Gilead Sciences, Inc. (GILD) may be ready to acquire New Haven, Conn.-based Achillion Pharmaceuticals, Inc. (ACHN). Given the company’s strong financial performance this year, many analysts believe Gilead is in the market for a strategic […]

Read More »

Mylan, Perrigo Notch Wins in Their Takeover Fight

Rival generic-drug makers Mylan NV and Perrigo Co. both chalked up wins this week in their hostile $36 billion takeover fight, which is heading into the homestretch. Mylan in April publicly bid for Perrigo, saying a combination would create a strong competitor in the quickly consolidating pharmaceuticals sector. Perrigo has rejected the price as too […]

Read More »

Avalanche drops eye drug trial, takes it back to lab

Drug developer Avalanche Biotechnologies Inc said it would not start a second mid-stage study of its eye drug, which showed only a modest improvement in vision in the first study. Avalanche’s shares fell 15 percent in extended trading on Thursday after closing at $13.83. The drug developer said it was stepping back from clinical trials […]

Read More »

Could Gilead Be Biotech’s Biggest Bargain?

Gilead Sciences (NASDAQ:GILD) shares may have rallied 24% this year, but better-than-expected sales and profit have led to analysts ratcheting up their EPS forecasts for next year and that’s kept a lid on its valuation. Given that Gilead Sciences’ forward P/E is below 10 and its shares are 5% off their June highs, the stock […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom